Sort   by:  
 Page size 
TranscriptomicsIGR_CAP1_DOCETAXEL_GE_STUDY_AC
'Prostate cancer is the second cancer diagnosed among men worldwide. Beside approval of new therapies in the last five years, chemotherapeutic agents, docetaxel and cabazitaxel taxanes remain key treatments for metastatic castration resistant prostate cancers. However, primary and acquired resistanc...
ORGANISM(S): Homo sapiens 
2018-11-07 | E-MTAB-4869 | biostudies-arrayexpress
TranscriptomicsIGR_CAP1_DOCETAXEL_GE_STUDY_NN
Docetaxel is used as a standard treatment in patients with metastatic castration-resistant prostate cancer. However, a large subset of patients develops resistance by mechanisms that remain largely unknown. It is thus important to define the relevant pathways implicated in docetaxel-resistance and v...
ORGANISM(S): Homo sapiens 
2013-06-30 | E-MTAB-1221 | biostudies-arrayexpress
UnknownExploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing.
Not available
S-EPMC7547099 | biostudies-literature
UnknownStable and high expression of Galectin-8 tightly controls metastatic progression of prostate cancer.
Not available
S-EPMC5546508 | biostudies-literature
UnknownTargeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.
Not available
S-EPMC3996665 | biostudies-literature
UnknownFunctional Assessment of Genetic Variants with Outcomes Adapted to Clinical Decision-Making.
Not available
S-EPMC4894565 | biostudies-literature
UnknownClusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis.
Not available
S-EPMC4931290 | biostudies-literature
UnknownReformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer.
Not available
S-EPMC9376089 | biostudies-literature
Sort   by:  
 Page size